Ranexa is CV Therapeutics’ Top Choice For Ranolazine Tradename
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ranexa is the lead tradename candidate for CV Therapeutics’ angina therapy ranolazine, the firm says. The name was filed with the Patent and Trademark Office for an agent to treat cardiovascular disease.